Vasopressin Research: What 49,699 Studies Show (2026) | RetatrutideCompare

Vasopressin — 49,699 studies indexed on PubMed. Activates V1a (vasoconstriction), V1b (ACTH release), and V2 (renal water reabsorption) receptors. Half-life: ~10–20 minutes. FDA status: FDA-approved.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on Vasopressin?

There are approximately 49,699 studies indexed on PubMed that mention Vasopressin (ADH, Antidiuretic Hormone), based on a search last updated 2026-06-18.

Is Vasopressin FDA-approved?

FDA status: FDA-approved.

How does Vasopressin work?

Activates V1a (vasoconstriction), V1b (ACTH release), and V2 (renal water reabsorption) receptors.

Activates V1a (vasoconstriction), V1b (ACTH release), and V2 (renal water reabsorption) receptors.

Reference facts

Also known as
ADH, Antidiuretic Hormone, Pitressin, AVP
Category
Hormonal & Pituitary
Mechanism of action
Activates V1a (vasoconstriction), V1b (ACTH release), and V2 (renal water reabsorption) receptors.
Targets
V1aR, V1bR, V2R
Indications under research or approved
Diabetes insipidus, Vasodilatory shock, Cardiac arrest (formerly)
Regulatory status (reference entry)
FDA-approved
Half-life
~10–20 minutes
Sequence
CYFQNCPRG
Sequence notes
Nonapeptide with Cys1-Cys6 disulfide bridge, C-terminal amide. Differs from Oxytocin at positions 3 (Phe vs Ile) and 8 (Arg vs Leu).
Molecular weight (Da)
1084
PDB accession
1JK4
First reported
1953

Primary References

Explore research articles about Vasopressin

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.